TLR4 and melanoma: To date, no clinical trial targeting TLR4 in HCC is ongoing, while the TLR4 agonist GLA-SE has been tested for the treatment of advanced soft-tissue sarcoma (NCT02180698, Phase I) and stage II-IV melanoma (NCT02320305, Early Phase I).